![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
LANNETT COMPANY, INC. (Amex: LCI) Formerly (OTC Bulletin Board: LANN), a manufacturer of pharmaceutical products, announced that the Food and Drug Administration has approved the reformulated version of its existing abbreviated new drug application ("ANDA") for Diphenoxylate HCL and Atropine Sulfate Tablets USP, 2.5 mg/0.025 mg, a generic version of Searle's Lomotil, indicated for the management of diarrhea. Lannett is currently working on approximately 15 new prescription product offerings. The company's current products serve a diverse range of medical treatments, including Attention-Deficit-Hyperactivity-Disorder, Pain Management, Irritable Bowel Syndrome, Allergies, Weight Management, Epilepsy, and AIDS. Lannett has approximately 80 employees and manufactures both prescription and over-the-counter generic drugs. lannett.com | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |